Why Retail Pharmacies Still Overcharge Uninsured Patients—And What That Means for Amazon

Consumer Reports recently published a fascinating survey of pharmacies’ cash prices for five common generic drug prescriptions. The results were startling. Prescription prices ranged from $66 to $1,351—a nearly 2,000% difference. The big three retail drugstore chains—CVS, Walgreens, and Rite Aid—consistently had higher average prices compared with those of other pharmacies. Independent pharmacies had some of the lowest prices, but also some of the highest prices. Our analysis of prescription profits highlights the pharmacy industry’s unfortunate pricing strategy for cash-pay prescriptions. Average profit margins ranged from $8 to $264 per prescription for the five drugs. We can only hope that … Continue reading Why Retail Pharmacies Still Overcharge Uninsured Patients—And What That Means for Amazon

The Rants – Marketing Buzz and ..

I was enjoying my day. The sea of Cortez appeared to sparkle as boats moved across her calmness. Then, it happened.  A hurricane? No.  A cruise ship allowing their customers to hurl bottles into the sea? No.  A press release from an LMS vendor that stated something not so accurate, but accurate enough. I admit I am hedging here trying the best way to say “yes, while parts of it is true, other parts are misleading,” because, it gives an impression of something – that anyone would think it. Course Marketplace as “System includes and or offers content” This is … Continue reading The Rants – Marketing Buzz and ..

Janssen’s New Transparency Report: A Peek Behind the Drug Pricing Curtain Raises Troubling Questions About Rebates

Johnson & Johnson’s Janssen business unit just released its 2017 Janssen U.S. Transparency Report. (Free download.) This is the second annual edition of the report, which provides a comprehensive look at Janssen’s commercial activities. Most notably, Janssen reveals that the list price for its pharmaceutical products grew by 8.1% in 2017. Its average net prices, however, declined in 2017 by 4.6%. Janssen paid $15 billion in rebates and discounts, which subtracted 42% from its list prices. Kudos to Janssen for providing so much disclosure. Below, I review some key takeaways from this valuable report. We’re left with some key unanswered … Continue reading Janssen’s New Transparency Report: A Peek Behind the Drug Pricing Curtain Raises Troubling Questions About Rebates

How a TMS can Keep Your Training Business Running Over the Festive Period

As the festive season approaches, your training business probably has quite a lot of things to worry about and plan for – the main one […] The post How a TMS can Keep Your Training Business Running Over the Festive Period appeared first on e-Learning Feeds. Powered by WPeMatico Continue reading How a TMS can Keep Your Training Business Running Over the Festive Period

The CVS-Aetna Deal: Five Industry and Drug Channel Implications

Surprise? CVS Health and Aetna announced their long-rumored merger. Relevant links below. This transaction will create a healthcare organization with significant market share in the pharmacy, pharmacy benefit management (PBM), and health insurance businesses. There could be many potential opportunities for new consumer-oriented offerings. Finding the consumer value in this multi-headed $221 billion behemoth will be a major challenge. Read on for my initial thoughts on the deal and what it means for PBMs, manufacturers, and pharmacies. I also highlight some of the implementation challenges. Feel free to add your own thoughts on this mega-deal in the comments below. (Yes, … Continue reading The CVS-Aetna Deal: Five Industry and Drug Channel Implications

Simplify Bug Tracking, Working with Remote Developers, Management Tools

zipBoard Digest Collaboration and Communication Simplify Bug Tracking Why the old system isn’t good enough : Bug tracking has increasingly expanded into the domains of the entire… Best […] The post Simplify Bug Tracking, Working with Remote Developers, Management Tools appeared first on e-Learning Feeds. Powered by WPeMatico Continue reading Simplify Bug Tracking, Working with Remote Developers, Management Tools

How to Leverage the Marketing Power of Social Proof

Association members encounter an overwhelming amount of information every day from organizations pushing themselves into the already crowded professional development space. No matter how hard […] The post How to Leverage the Marketing Power of Social Proof appeared first on e-Learning Feeds. Powered by WPeMatico Continue reading How to Leverage the Marketing Power of Social Proof

Generic Deflation Roils the Channel—And Will Get Worse

Deflation in generic drug prices dragged down second quarter earnings for drug wholesalers and generic manufacturers. Here’s a useful summary from The Wall Street Journal, which captures the grim marketplace realities in Falling U.S. Generic Drug Prices Hurt Manufacturers, Wholesalers. Yesterday, Mylan’s earning release noted “high-single-digit erosion expected in North America.” Below, I review the state of the generic drug market. As you will see, the overall market for mature generic drugs is deflating by about 10% per year. Many generic drugs have dropped significantly in price over the past four years. Surprisingly, the prices for about one in five … Continue reading Generic Deflation Roils the Channel—And Will Get Worse

What’s In, What’s Out: The New 2018 CVS Health and Express Scripts Formulary Exclusion Lists (Plus: A Sneak Peek From Prime)

This week, the two largest pharmacy benefit managers (PBMs)—Express Scripts and the CVS/caremark business of CVS Health—released updates to their 2018 formulary exclusion lists. They are available below for your downloading pleasure. For 2018, Express Scripts was more aggressive, expanding its list to 159 excluded products. At CVS Health, however, the total number of excluded remained steady. The Prime Therapeutics list won’t be available until September, but it will apparently exclude more drugs that either of its PBM peers. Read on for my 2018 head-to-head comparison, including comments on inflammatory conditions, multiple sclerosis, epinephrine, biosimilars, and more. I also review … Continue reading What’s In, What’s Out: The New 2018 CVS Health and Express Scripts Formulary Exclusion Lists (Plus: A Sneak Peek From Prime)